Skip to Content

Clinical Trial News

This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.

MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence

Posted today in Clinical Trials

LA JOLLA, Calif., June 30, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the clinical trial of MN-166 (ibudilast) in alcohol dependence has completed enrollment of 24 subjects. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of...

Read more...

Juno Announces FDA Acceptance of Investigational NDA for JCAR017 in Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

Posted yesterday in Clinical Trials

SEATTLE, June 29, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) accepted the Company's investigational new drug (IND) application for JCAR017 for patients with relapsed/refractory (r/r) B cell non-Hodgkin lymphoma, or NHL....

Read more...

Immune Pharmaceuticals Initiates Phase II Clinical Trials With Bertilimumab in Ulcerative Colitis and Bullous Pemphigoid

Posted 5 days ago in Clinical Trials

NEW YORK, June 25, 2015 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced today that it has initiated its Phase II Ulcerative Colitis clinical trial and is scheduled to initiate its Phase II Bullous Pemphigoid clinical trial on July 1, 2015. Study Initiation is the training of hospital staff to allow for patient screening and immediate patient enrollment into the clinical trial upon...

Read more...

Abbvie Announces New Phase 3B Results in Genotype 1B Chronic Hepatitis C Patients with Compensated Liver Cirrhosis

Posted 5 days ago in Clinical Trials

NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected adult patients with compensated liver cirrhosis.1 Patients received 12 weeks of Viekirax...

Read more...

Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial of Plecanatide in Patients with IBS with Constipation

Posted 7 days ago in Clinical Trials

NEW YORK, June 23, 2015 -- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today the initiation of the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in patients with irritable bowel syndrome with constipation (IBS-C). The phase 3 IBS-C program includes two randomized, 12-week,...

Read more...

Paratek Doses First Patient in Phase 3 Clinical Trial of Omadacycline in Acute Bacterial Skin and Skin Structure Infections

Posted 7 days ago in Clinical Trials

BOSTON, June 23, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry today announced the dosing of the first patient in its Phase 3 clinical trial of its lead drug candidate, omadacycline, for the treatment of Acute Bacterial Skin and Skin Structure Infections...

Read more...

Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A for Andexanet Alfa

Posted 8 days ago in Clinical Trials

June 22, 2015 -- Portola Pharmaceuticals (NASDAQ: PTLA), Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced full results from the second part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Apixaban) study. This registration-enabling study evaluated the safety and efficacy of andexanet alfa, an investigational antidote...

Read more...

Regulatory Update on Divestment of Nimenrix and Mencevax

Posted 8 days ago in Clinical Trials

London UK, 22 June 2015 -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced it is divesting its meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals (a subsidiary of Pfizer Inc). The sale follows commitments given to the European Commission and other regulators in connection with the merger control clearances obtained for GSK’s three-part transaction with Novartis AG, which completed...

Read more...

ImMucin Granted Orphan Drug Designation for the Treatment of Multiple Myeloma

Posted 8 days ago in Clinical Trials

Ness Ziona, 22nd June 2015. Vaxil Bio, (TASE: VAXL) a company specializing in the development of immunotherapy-based drugs, reports today that its lead product, ImMucin, has been granted an “orphan drug” designation by the US Food and Drug Administration (FDA), for the treatment of multiple myeloma (MM). ImMucin is an immunotherapeutic treatment which educates the MM patient's immune system, particularly...

Read more...

Tekmira Provides Update on TKM-Ebola-Guinea

Posted 11 days ago in Clinical Trials

VANCOUVER, British Columbia and DOYLESTOWN, Pa., June 19, 2015 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced that the Phase II clinical trial of TKM-Ebola-Guinea has reached a predefined statistical endpoint and enrollment has been closed. The endpoint...

Read more...

BeiGene Announces IND Approval for BGB-3111, a Bruton Tyrosine Kinase Inhibitor

Posted 11 days ago in Clinical Trials

BEIJING, China (June 19, 2015)—BeiGene Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the clinical development of BGB-3111, a proprietary Bruton tyrosine kinase (BTK) inhibitor for the treatment of B-cell malignancies....

Read more...

Updated Results From Phase 2 Clinical Trial of TG-1101 (Ublituximab)

Posted 12 days ago in Clinical Trials

NEW YORK, June 18, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), today announced updated clinical results from its Phase 2 study of TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib, the oral BTK inhibitor. The updated results from the Phase 2 study were delivered in an oral presentation by Dr. John Burke, Rocky Mountain Cancer...

Read more...

Ocular Therapeutix Begins Enrollment in Phase 3 Clinical Trial for Dextenza for the Treatment of Allergic Conjunctivitis

Posted 2 weeks ago in Clinical Trials

BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 16, 2015-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today enrollment of the first patients in a Phase 3 clinical trial to evaluate the safety and efficacy of Dextenza (sustained release dexamethasone, 0.4mg) for the treatment of...

Read more...

Genzyme Initiates Phase 1/2 Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients

Posted 2 weeks ago in Clinical Trials

CAMBRIDGE, Mass., June 15, 2015 --(BUSINESS WIRE)--Genzyme, a Sanofi company, announced today that the first pediatric patient has begun treatment in a Phase 1/2 clinical trial focused on evaluating the investigational therapy olipudase alfa. Olipudase alfa is an enzyme replacement therapy being studied for the treatment of nonneurological manifestations of acid sphingomyelinase deficiency (ASMD), also known as...

Read more...

Corbus Pharmaceuticals Announces FDA Orphan Drug Designation for Resunab for the Treatment of Systemic Sclerosis (Scleroderma)

Posted 2 weeks ago in Clinical Trials

NORWOOD, MA -- (Marketwired) -- 06/12/15 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the U.S. Food and Drug Administration ("FDA") has granted Corbus' lead drug candidate Resunab Orphan Drug Designation for the treatment of systemic...

Read more...

Pacritinib Phase 3 Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis

Posted 2 weeks ago in Clinical Trials

VIENNA, June 12, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (nasdaq and mta:CTIC) and Baxter International's BioScience business BAX, +0.00% today announced new patient-reported outcome (PRO) data for pacritinib – an investigational oral multikinase inhibitor with specificity for JAK2 and FLT3 – from the Phase 3 PERSIST-1 study. As recently reported at the American Society of Clinical Oncology...

Read more...

Adamas Begins Phase 2 Clinical Trial Assessing ADS-5102 for Treating Multiple Sclerosis Symptoms in Patients With Walking Impairment

Posted 2 weeks ago in Clinical Trials

EMERYVILLE, Calif., June 11, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced today the initiation of a Phase 2 clinical trial with ADS-5102 (amantadine HCl) in individuals with multiple sclerosis (MS) who have walking impairment. "We are pleased to initiate this Phase 2 trial in MS patients with walking impairment to further our understanding of the safety and tolerability of...

Read more...

FORUM Pharmaceuticals Inc. Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial Program of Encenicline for Cognitive Impairment in Schizophrenia

Posted 2 weeks ago in Clinical Trials

WALTHAM, Mass. – June 11, 2015 – FORUM Pharmaceuticals Inc., a biopharmaceutical company singularly focused on the development and delivery of innovative medicines to treat serious brain diseases, today announced the completion of patient enrollment in its two pivotal Phase 3 clinical trials investigating the use of encenicline to treat cognitive impairment in schizophrenia. The Phase 3 clinical trial program,...

Read more...

Studies Show Psoriasis Patients Achieved Significant Levels Of Skin Clearance And Improved Quality Of Life After 12 Weeks Of Ixekizumab Treatment

Posted 2 weeks ago in Clinical Trials

INDIANAPOLIS, June 10, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that detailed results of two pivotal Phase III studies for ixekizumab were published by The Lancet. The UNCOVER-2 and UNCOVER-3 clinical studies of more than 2,500 patients found ixekizumab to be statistically superior to etanercept and placebo on all measures of skin clearance. Patients treated with ixekizumab also...

Read more...

Lilly and Incyte Unveil Detailed Data on Two Pivotal Studies of Baricitinib in Rheumatoid Arthritis

Posted 2 weeks ago in Clinical Trials

INDIANAPOLIS, June 10, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that five abstracts featuring data from three clinical studies and separate pharmacology studies for its investigational rheumatoid arthritis drug baricitinib will be presented at the 2015 annual meeting of the European League Against Rheumatism in Rome June 10-13. Lilly and Incyte...

Read more...
Older articles
(web4)